Myotonic dystrophy type 1
Conditions
Interventions
None listed
Sponsors
Dystrophia Myotonica: Clinical Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Genetically diagnosed 2.Fasting BS > 130mg/dl or 7.0% < HbA1c < 10.0% 3.Fasting serum C-peptide > 1.0mg/ml 4.Oral intake 5.Without limitation for stage or severity of disease
Exclusion criteria
Exclusion criteria: 1.Medicated by insulin, DPP-4 inhibitor or GLP-1 agonist 2.Serious infection, perioperative or serious injury 3.Cardio-vascular event 4.Proronged QT on ECG 5.Serious liver damage 6.Moderate or serious renal damage 7.Moderate or serious heart failure 8.Gestation or lactation period 9.Short bowel syndrome 10.Medicated by steroid, interferon, hormonal agent, atypical antipsychotic, IA antiarrhythmic agent or III antiarrhythmic agent 11.Emaciation or skin disease with difficulty to be attached CGM 12.No informed consent with a form 13.Assessed as inadequate by a physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation before and after administration of DPP-4 inhibitor. Index by CGM (mean blood sugar (BS), SD of BS, M value, MAGE, BS area, proportion of hypoglycemia or hyperglycemia) and routine blood examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event | — |
Countries
Japan
Contacts
Public ContactHiroto TAKADA
National Aomori Hospital Neurology
Outcome results
None listed